Bicoll supports the development of a drug candidate for Huntington’s disease in collaboration with Galyan Bio

Galyan Bio is developing orally available small molecules for neurodegenerative diseases. We are employing AI-driven de novo drug design methods to identify new scaffold for first-in-class clinical candidates. The new treatments interfere in the protein quality control system and are subsequently also useful for healthy aging.